Disclosed are antibodies that interact with a matrix metalloproteases such
as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies
can be used, e.g., to treat or prevent metastatic disorders,
hyperproliferative disorders, disorders which are characterized by
excessive extracellular matrix degradation, and inflammatory disorders.